MS Tech Secures $1.2M R&D Grant for Early Disease Detection Biosensors

MS Tech Ltd. has announced a $1.2 million R&D grant from the Israel Innovation Authority for its Bio-Medical Division, aimed at advancing biosensor technology for early disease detection through liquid biopsies. This grant underscores the division's leadership in developing cutting-edge biosensors that promise to revolutionize early diagnostics by enabling fast, point-of-care results.

The innovative biosensors developed by MS Tech are designed to overcome the limitations of current liquid biopsy analyses, which are often costly and time-consuming, requiring laboratory-based instrumentation. By integrating IoT capabilities, these biosensors facilitate immediate data-driven decisions, significantly reducing operational delays in diagnostics.

At the heart of MS Tech's advancements is the HF-QCM sensor technology, which represents a convergence of biology, life sciences, engineering, and software. This technology has broad applications across medical diagnostics, agriculture, food security, and environmental protection, showcasing its potential to impact various sectors significantly.

Doron Shalom, CEO of MS Tech, expressed gratitude for the recognition from the Israel Innovation Authority, highlighting the company's commitment to innovation since its establishment in 1998. The grant is part of the LIQUIDBX Consortium's efforts to develop a technological infrastructure for early disease detection, combining novel biosensors with artificial intelligence and advanced learning algorithms.